| NextCure is a clinical-stage biopharmaceutical company engaged on discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Co.'s primary product candidate, NC318, is an immunomedicine against an immunomodulatory protein called Siglec-15. Co.'s second product candidate, NC410, is an immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1. Co.'s third product candidate, NC762, is an immunomedicine targeting a molecule called human B7 homolog 4 protein. We show 14 historical shares outstanding datapoints in our NXTC shares outstanding history coverage, used to compute NXTC market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing NXTC market cap history over the course of time is important for investors
interested in comparing NXTC's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of NXTC versus a peer is one thing; comparing
NXTC market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like NXTC can fluctuate over the course of history.
With this page we aim to empower investors researching NXTC by allowing them to research the NXTC market cap history.